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Abstract
Background: Co-infection with HIV-1 and HCV is a significant global public health problem and a major consideration for
anti-HIV-1 treatment. HCV infection among HIV-1 positive people who are eligible for the newly launched nationwide anti-
HIV-1 treatment program in China has not been well characterized.
Methodology: A nationwide survey of HIV-1 positive injection drug uses (IDU), former paid blood donors (FBD), and sexually
transmitted cases from multiple provinces including the four most affected provinces in China was conducted. HCV prevalence
and genetic diversity were determined. We found that IDU and FBD have extremely high rates of HCV infection (97% and 93%,
respectively). Surprisingly, people who acquired HIV-1 through sexual contact also had a higher rate of HCV infection (20%) than
the general population. HIV-1 subtype and HCV genotypes were amazingly similar among FBD from multiple provinces
stretching from Central to Northeast China. However, although patterns of overland trafficking of heroin and distinct HIV-1
subtypes could be detected among IDU, HCV genotypes of IDU were more diverse and exhibited significant regional differences.
Conclusion: Emerging HIV-1 and HCV co-infection and possible sexual transmission of HCV in China require urgent
prevention measures and should be taken into consideration in the nationwide antiretroviral treatment program.
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Introduction
Hepatitis C virus (HCV) is a single-stranded RNA flavivirus that
was first recognized as the cause of non-A-non-B hepatitis [1,2].
The HCV epidemic now affects over 200 million people
worldwide. Co-infection with HCV and HIV-1 is also a significant
global public health problem and has been shown to increase
HCV viral loads and promote the development of cirrhosis and
progression to end-stage liver disease [3–6]. Whether co-infection
with HIV-1 and HCV results in a faster progression to AIDS
remains controversial [7,8]. More importantly, co-infection with
these two viruses will continue to cause increased morbidity and
mortality in many developing countries, where treatment for either
virus is still largely unavailable [9,10].
In China, the HIV-1 epidemic has been carefully followed among
i n j e c t i o nd r u gu s e r s( I D U s )s i n c ei t se m e r g e n c ei nY u n n a nP r o v i n c e
in the late 1980s [11,12]. More recently, emerging HIV-1 epidemics
among IDUs in other parts of China have been linked to heroin
trafficking routes[13–18]. HIV-1 infectionwasalso a serious problem
among former paid blood donors in China during 1990s and is now
spreading among people who are sex partners of high-risk
populations [19,20]. Relatively less is known about the spread of
HCV infectionand HCV/HIV-1co-infection in China [21–24]. Few
population-based studies have been performed in China to
systematically examine co-infection with HIV-1 and HCV in IDUs,
former paid blood donors (FBD), or those who have acquired HIV-1
through sexual contact (SC). The distribution of HCV genotypes
among various risk groups has not been systematically evaluated. It is
also not clear how widespread the HCV epidemic is in China and
whether there is any spreading pattern of HCV infection.
The aim of the present study was to investigate the problem of
HCV infection among HIV-1-infected people from various risk
groups in China and to determine the HCV genotype
distribution in these individuals. High rates of HCV infection
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groups including IDUs, PBDs, and sexually transmitted cases.
Distinct HIV-1 and HCV genotypes were identified according
to risk groups and regional differences in the distribution of
HCV genotypes among IDUs were observed. Our data have
important implications for HIV-1 and HCV transmission and
treatment in China.
Results
High prevalence of HCV infection among HIV-1-positive
subjects in high-risk groups in China
To systematically evaluate the problem of HIV-1/HCV co-
infection, we analyzed samples from a total of 178 HIV-1-
infected IDUs from Yunnan, Xinjiang, and Guangxi provinces,
128 FBD from Henan, Jilin, and Liaoning provinces, and 159 SC
from the same six provinces (Fig. 1). IDUs from Yunnan,
Guangxi, and Xinjiang provinces were studied because injection
drug use and HIV-1 infection are most problematic in these
provinces in China [20]. Although HIV-1 infection among FBD
is known to be a major problem in Henan province, the HIV-1
infection that has also been detected among FBD in the
Northeast provinces Jilin and Liaoning has not been well
characterized to date (Fig. 1).
We found that the prevalence of HCV in HIV-1-infected
subjects was 96.6% in IDUs and 92.9% in FBD (Table 1). There
was no significant difference in HCV prevalence among IDUs
from different provinces (Table 2). The prevalence of HCV
infection among HIV-1 positive FBD from Henan was somewhat
higher than that from Liaonin, or Jilin provinces (Table 2). The
extremely high prevalence of HCV among HIV-1-positive IDUs
and FBD is consistent with the common transmission mechanism
of both viruses. Remarkably, we also detected high rate of HCV
infection (20.1%) among people who acquired HIV-1 infection
through sexual contacts i.e. SC subjects (Table 1). Although the
HCV prevalence among HIV-1-positive SC subjects was lower
than that in IDUs and FBD, it was still significantly higher than
the HCV prevalence reported for the general population. For
example, the HCV prevalence in more than 160,000 voluntary
blood donors from large cities in China such as Beijing,
Chongqing, and Jinan has been reported to be ,1% [25–27].
We have also observed low HCV prevalence rates among 10,078
outpatients and inpatients in a Liaoning provincial hospital
(Table 1). Furthermore, among 30,296 subjects who underwent
routing health examination, only 166 (0.55%) were found to be
HCV positive. Thus, HIV-1-infected people apparently have high
rates of HCV co-infection, regardless of the risk factors for HIV-1
acquisition.
Figure 1. Map of HIV-1 and HCV distribution in China. IDUs from Yunnan, Guangxi, and Xinjiang provinces were studied because injection
drug use and HIV-1 infection are most problematic in these provinces in China [20]. Spreading of CRF07 and CRF08 among IDUs has been detected in
Yunnan, Guangxi, and Xinjiang provinces in China along the drug trafficking routes (arrows). However, HCV genotypes among IDUs from these
provinces are distinct (pie charts). HCV genotyping among FBD in Henan, Jilin, and Liaoning provinces showed another difference from IDU.
doi:10.1371/journal.pone.0010631.g001
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groups
Overland drug trafficking has been linked to the emergence of
novel recombinant strains of HIV-1 and the spread of HIV-1
infection among drug users in China [13–18]. CRF-07 and CRF-
08 are subtype B and C recombinant viruses (CRF-BC) that have
their origin in Yunnan province [13–18]. CRF07 spread along the
ancient silk road to Xinjiang from Yunnan among IDUs, and
CRF08 spread eastward from Yunnan to Guangxi province
[13–18]. HIV-1 subtypes were determined for 127 (IDUs) from
Yunnan, Guangxi, and Xinjiang provinces. Consistent with
previous reports [13–18], CRF-BC recombinant HIV-1 strains
were the predominant HIV-1 strains in IDUs in areas along these
shared drug trafficking routes (Table 3). On the other hand, HIV-
1 subtype B’ was the predominant HIV-1 subtype among FBD in
Henan, consistent with previous observations [22]. For the first
time, we have observed that HIV-1 subtype B’ is also the
predominant HIV-1 subtype among FBD in the Northeast
provinces of Liaonin and Jilin (Table 3). Since Henan and Jilin
provinces are far away (.1,000 km) from each other, our data
suggest that certain paid former blood donors may travel long
distance from one place to another, causing the spread of HIV-1
infection in the same risk group. Overall, distinct HIV-1 subtypes
were confined within the IDU and FBD populations from
geographically separated provinces in China.
HCV genotyping
Molecular epidemiology of HIV-1 infection has been monitored
since the beginning of the HIV-1 epidemic in China. This analysis
has led to the identification of emerging transmission of HIV-1
from IDUs in Yunnan to those in Xinjiang and Guangxi [13–18].
To determine whether HCV genotyping could also be used to
monitor the pattern of HCV transmission and drug trafficking,
HCV genotypes were determined and compared for IDUs from
Yunnan, Xinjiang, and Guangxi provinces. Phylogenetic analysis
of HCV sequences from China indicated the existence of HCV 1a,
1b, 2a, 3a, 3b, and various 6 genotypes (Fig. 2 and supplemental
Figures S1, S2 and S3).
Samples from Yunnan IDUs were classified into genotypes 1a,
1b, 3a, 3b, and various 6 genotypes (Table 4). Genotype 6 was the
major HCV genotype (.50%) in IDUs in Yunnan. However,
genotype 6 was almost absent (in only 1 of 23 individuals) from
IDUs in Xinjiang. On the other hand, genotype 3 HCV accounted
for .70% of all IDUs in Xinjiang, as compared to 40% of IDUs in
Yunnan. Furthermore, although genotype 6 was detected among
IDUs in both Yunnan and Guangxi, IDUs in Guangxi were
mostly genotype 6a, while IDUs in Yunnan were mostly genotype
6n and a new genotype 6u (Table 4).
HCV genotypes in FBD from central and northeast China were
more homogenous than were those in IDUs. Only genotypes 1b
and 2a were detected, and genotype 1b was the predominant form
in FBD from all three provinces (Table 4). Surprisingly, although
diverse HCV genotypes were detected among IDUs in China,
genotype 2a HCV was completely absent from all the IDUs
examined.
The detection of diverse HCV genotype 6 sequences in Yunnan
was interesting (Table 4). Thus the phylogenetic analysis of these
diverse HCV genotype 6 sequences was performed using well
characterized genotype 6 reference sequences (Fig. 3). A cluster of
genotype 6 sequences grouped with the recently identified
genotype 6u sequences [28–30]. One sequence grouped with the
recently identified genotype 6v sequences [31]. Furthermore,
although some sequences clustered with genotype 6n, several
sequences, such as c143, c176, and c178, fell between 6n and 6m.
Table 1. HCV prevalence among HIV-1 positive subjects from various risk groups in China.
HIV-1+ HCV+ Mean Age Sex male/femal
Injection drug users (IDU) 96.6% (172/178) 28.969.7 162/10
Former paid plasma donor (FPD) 92.9% (119/128) 42.669.4 73/46
People who acquired HIV-1 through sexual contact (SC) 20.1% (32/159) 37.969.0 16/16
Hospital outpatients 1.55% (87/5610)
Hospital inpatients
Routing health examination
1.23% (55/4468)
0.55% (166/30,294)
General outpatients and inpatients were also evaluated as controls.
doi:10.1371/journal.pone.0010631.t001
Table 2. HCV prevalence among HIV-1 positive subjects from
different provinces in China.
Risk
factors Location
Risk Location
factors
FBD IDU
Henan 96.6% (84/87) Guangxi 95.0% (96/101)
Liaonin 86.7% (13/15) Xinjiang 95. 8% (23/24)
Jilin 84.6%(22/26) Yunnan 100%(53/53)
doi:10.1371/journal.pone.0010631.t002
Table 3. Distribution of HIV-1 subtypes in different provinces
from China.
Risk
factors Location HIV-1 subtypes
B’ B CRF01-AE CRF-BC CRF02-AG C
FBD
Henan 84 3 0 0 0 0
L i a o n i n 1 5 0 00 00
Jilin 26 0 0 0 0 0
IDU
Guangxi 0 0 2 48 0 0
Xinjiang 0 0 0 24 0 0
Yunnan 0 0 1 52 0 0
doi:10.1371/journal.pone.0010631.t003
HIV-1/HCV Coinfection in China
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was quite remarkable.
Discussion
Injection drug use in China was the driving force for the original
HIV-1 epidemic and continues to be a major source of HIV-1
infection [19,20]. Yunnan, Xinjiang, and Guangxi provinces carry
the majority of the HIV-1 cases among IDUs in China. During the
1990s, HIV-1 infection in FBD in central China became another
major source of HIV-1 infection in China [19,20]. Although many
cases have been reported from Henan Province, FBD-related
HIV-1 infections have also affected other provinces, such as
Liaoning and Jilin in the northeast region of China. In recent
years, sexual transmission of HIV-1 in China has also increased
significantly [19,20] and now represents a major threat to the
general population.
The current study indicates that HCV infection is a major
problem for HIV-1-infected individuals, regardless of the route of
transmission: injection drug use, paid blood donation, or sexual
contact. The high rate of HCV and HIV-1 co-infection is a major
public health concern. HCV is now a major opportunistic
infection for those people who are infected with HIV-1. Previous
studies have shown that HIV-1/HCV co-infections increase the
HCV viral load and progression to end-stage liver disease (ESLD),
hepatocarcinoma, and hepatic-related death. HCV infection has
also been reported to result in a higher risk of AIDS-defining
illnesses, AIDS-related death, and hospitalization in HCV/HIV-1
co-infected patients.
It is estimated that more than 30,000 HIV-1-infected patients
have been enrolled in the nationwide antiretroviral treatment
program in China [19]. HCV positive subjects in China have low
viral clearance rates [32]. The high rate of co-infection with HCV
among HIV-1-infected patients represents a major challenge for
the treatment of HIV-1-infected people in China [10,33]. HCV-
related liver disease has emerged as a leading cause of death in
people who undergo highly active antiretroviral treatment [10,33].
Thus, HIV-1 mono-therapy may have limited benefit for HCV/
HIV-1 co-infected patients. Furthermore, the efficacy and liver
toxicity of anti-HIV-1 drugs in these co-infected patients have to
be considered and carefully monitored during HIV-1 treatment
[34,35].
Sexual transmission of HCV has been documented [10,33].
However,thefrequencyandextentofthissexualtransmissionremain
controversial. Our study has revealed a significantly high prevalence
of HCV infection among HIV-1-positive subjects who acquired HIV-
1 through sexual contact. The HCV prevalence (20%) among HIV-
1-positive SC subjects was clearly higher than that in volunteer blood
donors (,1%) from various provinces across China. We have also
found that bothinpatients and outpatients in a Liaoning hospital have
much lower HCV prevalence than do SC. Strategies to reduce the
transmission of HCV among spouses and sex partners of HCV-
positive people are urgently needed.
Overland heroin trafficking routes have been associated with
dual epidemics of injection drug use and HIV-1 infection in
China [13–18]. The molecular epidemiology of HIV-1 subtypes
among IDUs from several provinces, including Yunnan,
Guangxi, and Xinjiang, has indicated that the CRF07 and
CRF08 BC recombinant viruses have spread along distinct drug
trafficking routes. In IDUs, HCV is transmitted through risk
behaviors similar to those that transmit HIV-1. However, the
HCV genotypes in IDUs from different provinces did not match
the patterns of HIV-1 transmission and drug trafficking. For
example, the most common HCV genotype detected among
IDUs in Yunnan was genotype 6 (6n and 6u). However, genotype
6 HCV was almost absent from IDUs from Xinjiang, where
genotype 3 (3a and 3b) accounted for about 70% of all HCV
infections. In Guangxi, genotype 6 was also less prevalent among
IDUs (Table 3). Furthermore, although genotype 6 was detected
among IDUs in both Yunnan and Guangxi, IDUs in Guangxi
were mostly genotype 6a, while IDUs in Yunnan were mostly
genotypes 6n and 6u of HCV (Fig. 2). Thus, while molecular
epidemiology of HIV-1 is useful for tracking the spreading
pattern of HIV-1 infection and heroin trafficking routes in China,
this approach may prove less helpful for HCV molecular
genotyping. The high diversity of HCV genotypes that we
observed in China may also have implications for future HCV
treatment.
Methods
Study participants and serological testing
HIV-1 positive subjects from several major provinces in China
were recruited between 2000 and 2008 by the Provincial Center
for Disease Control. This study was approved by the institution’s
ethical committee. The study participants were interviewed by
clinicians to determine their epidemiologic background, using
questionnaires designed by the UNAIDS HIV-1 characterization
network. Study subjects included 159 individuals with sexual risk,
128 former paid blood donors (FBD), and 178 injection drug users
(IDUs). The presence of HIV-1 antibody was determined by
enzyme-linked immunosorbent assay (ELISA) using the Vironos-
Figure 2. Neighbor-joining tree demonstrating that Hepatitis C virus sequences from China belong to 1a, 1b, 2a, 3a, 3b, and 6
genotypes. Sequences analyzed here contain 306 nucleotides, corresponding to 350–655 of H77 genome. The tree was drawn with MEGA 4 (Build
#4028)[36], using Kimura 2-parameter as the model. The references were obtained from the Los Alamos National Laboratory HCV Databases (http://
hcv.lanl.gov/content/index). Bootstrap values .70% are indicated at the nodes of the corresponding branches.
doi:10.1371/journal.pone.0010631.g002
Table 4. Distribution of HCV genotypes in different provinces
from China.
Risk
factors Location HCV genotypes
1a 1b 2a 3a 3b 6a 6e 6n 6u/v
FBD Henan 0 37 24 0 0 0
Liaoning 0 51000
Jilin 0 84000
IDU Yunnan 2 1081 4 2 1 1 1 3
Xinjiang 0 60791
G u a n g x i 1 1 1012 4 8 2
Sex Liaoning 0 10000
H e n a n 052010
Xinjiang 0 30210
Yunnan 1 00010 1
doi:10.1371/journal.pone.0010631.t004
HIV-1/HCV Coinfection in China
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samples were not considered HIV-1-positive until confirmation by
the HIV-1/2 Western blot immune assay (Gene Lab, Singapore).
Hepatitis C antibody was analyzed using the Ortho HCV Version
3.0 ELISA Test System (Ortho Diagnostic Systems, Raritan, NJ,
USA).
RNA purification, PCR amplification, sequencing, and
phylogenetic analysis
HIV-1 RNA was extracted from plasma by a column
purification method (QIAampH Viral RNA Mini Kit, Qiagen,
Hilden, Germany) and subjected to reverse transcription-nested
PCR. The nucleotide sequence of the 2.6-kb gag-reverse
transcriptase (RT) gene (nucleotide position relative to HXB2
genome: 790-3421) was determined by direct sequencing (ABI
PRISMH 3130 Genetic Analyzer, Applied Biosystems, Foster City,
CA, USA). The PCR primer-binding sites for the amplicon were
based on published sequences of geographical variants and were as
highly conserved as possible. Codon alignment of query sequences
with various HIV-1 reference subtypes and CRFs from the HIV-1
database (http://HIV-web.lanl.gov/) was performed. Selected
HIV-1 subtypes/CRFs of geographical importance were also
included in the alignment. Phylogenetic and molecular evolution-
ary distances were estimated using the neighbor-joining method
and the Kimura 2-parameter model with a transition-transversion
ratio of 2.0. The reliability of the branching orders was tested by
bootstrap analysis of 1,000 replicates. Bootscanning, similarity
plots, and informative site analysis were performed using SimPlot
v3.5[11] to define the recombination structure. All RNA
extractions and PCR amplifications were carried out with
appropriate negative controls to detect possible contamination
during the procedure. To check for potential contamination, the
sequences obtained were compared to all known sequences in the
HIV-1 database by a BLAST search (http://HIV-web.lanl.gov/
content/index) prior to analysis.
RNA for HCV genotyping was extracted from 100 mL of serum
using the QIAamp Viral RNA kit (QIAGEN Inc, Valencia, CA,
USA). Reverse transcription and nested PCR were performed
using primers for conserved regions of Core as previously
described [23]. After purification with the QIAquick PCR
Purification kit (QIAGEN Inc, Valencia, CA), samples were
sequenced using the inner forward primer on an automated
sequencer (PRISM, version 2.1.1; ABI). Sequences were compiled
using the BioEdit program, version 4.7 (T. Hall, North Carolina
State University, Raleigh), and genotypes were assigned after
alignment with known HCV genotypes as previously described
[23].
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Supporting Information
Figure S1 Neighbor-joining subtree demonstrating that Hepa-
titis C virus sequences from China belong to genotype 1. The tree
was drawn with MEGA 4 (Build #4028), using Kimura 2-
parameter as the model. The references were obtained from the
Los Alamos National Laboratory HCV Databases (http://hcv.
lanl.gov/content/index). Bootstrap values .70% are indicated at
the nodes of the corresponding branches. Symbol N indicates the
sequence is from a PBD sample, while & is from IDU.
Found at: doi:10.1371/journal.pone.0010631.s001 (0.82 MB JPG)
Figure S2 Neighbor-joining subtree demonstrating that Hepa-
titis C virus sequences from China belong to genotype 2. The tree
was drawn with MEGA 4 (Build #4028), using Kimura 2-
parameter as the model. The references were obtained from the
Los Alamos National Laboratory HCV Databases (http://hcv.
lanl.gov/content/index). Bootstrap values .70% are indicated at
the nodes of the corresponding branches. Symbol N indicates the
sequence is from a PBD sample, while & is from IDU.
Found at: doi:10.1371/journal.pone.0010631.s002 (0.75 MB JPG)
Figure S3 Neighbor-joining subtree demonstrating that Hepa-
titis C virus sequences from China belong to genotype 3. The tree
was drawn with MEGA 4 (Build #4028), using Kimura 2-
parameter as the model. The references were obtained from the
Los Alamos National Laboratory HCV Databases (http://hcv.
lanl.gov/content/index). Bootstrap values .70% are indicated at
the nodes of the corresponding branches. Symbol & indicates the
sequence is from an IDU sample.
Found at: doi:10.1371/journal.pone.0010631.s003 (0.77 MB JPG)
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